机译:Neoadjuvant imatinib在先进的主要或局部复发性皮肤刺激arco arcuberans:多中心二期倾向试验,长期随访
Department of Dermatology University of Würzburg Würzburg Germany;
Dermatopathology Bodensee Friedrichshafen Germany;
Skin Cancer Unit German Cancer Research Center Heidelberg Germany Department of Dermatology;
Department of Dermatology University Hospital Heidelberg Heidelberg Germany Department of;
Department of Dermatology Elbe Klinikum Buxtehude Buxtehude Germany;
Department of Dermatology Saarland University Hospital Homburg Saarland Germany;
Department of Dermatology University Hospital of Münster Münster Germany;
Department of Dermatology University of Kiel Kiel Germany;
Department of Dermatology Technical University Munich Munich Germany;
Department of Dermatology University Hospital Erlangen Erlangen Germany;
Department of Dermatology Helios Klinikum Erfurt Erfurt Germany;
Department of Dermatology University Medical Center Mannheim University of Heidelberg Mannheim;
Department of Dermatology Medical University Graz Graz Austria;
Department of Pathology University of G?ttingen G?ttingen Germany;
Department of Dermatology University of Essen Essen Germany;
机译:Neoadjuvant imatinib在先进的主要或局部复发性皮肤刺激arco arcuberans:多中心二期倾向试验,长期随访
机译:甲磺酸伊马替尼新辅助/辅助治疗晚期原发性和转移性/复发性胃肠道间质瘤的II期试验:放射治疗肿瘤学0132组的长期随访结果。
机译:勘误至:甲磺酸伊马替尼的新辅助/辅助治疗晚期原发性和转移性/复发性可操作胃肠道间质瘤的II期试验:放射治疗肿瘤学0132组的长期随访结果
机译:在MADIT II患者常规随访的预期多中心比较试验:额外访问和成本影响
机译:新辅助的II期临床试验/佐剂甲磺酸伊马替尼高级原发性和转移性/复发可操作的胃肠道间质瘤放射治疗肿瘤0132集团的长期随访结果
机译:晚期皮肤皮肤纤维肉瘤的甲磺酸伊马替尼:两项II期临床试验的合并分析